Review



human prostate cancer tissue microarray tma  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Novus Biologicals human prostate cancer tissue microarray tma
    Human Prostate Cancer Tissue Microarray Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/Human+Prostate+Tissue+MicroArray+(Cancer)/pm36084759-113-0-9
    Average 90 stars, based on 23 article reviews
    human prostate cancer tissue microarray tma - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Staining:

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: .. Staining of metastatic colon cancer under the same conditions is shown as a positive control. (B–E) Normal human TMAs (FDA999w from BioMAx, B and C and FDA999-1 from US Biolabs, D and E), each containing 32 different tissues with replicates from 3 different individuals, along with a prostate cancer microarray (NBP2-30169 from Novus Biologicals) were stained with/without GlyTR1 with detection by anti6xHis-HRP antibody. ..

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens
    Article Snippet: Human colorectal carcinoma progression tissue microarray (CHTN-CRC2, Cooperative Human Tissue Network, University of Virginia) was stained with GlyTR1-FITC at 5 μg/mL before analysis by immunofluorescent microscopy (Aperio Versa 200, Model DM6 B, Leica). .. Human tissue microarrays from US Biomax (FDA999u, FDA999w and BR1005b), US Biolabs (FDA999-1), Novus Biologicals (NBP2-30169) and mouse (C57BL/6) tissue microarray from Pantomics (AMS545) were stained with L-PHA-biotin (0.25 μg/mL for FDA999u), GlyTR1 (0.5 μg/mL for FDA999w or 0.67 μg/mL for FDA999-1) or GlyTR2 (3 μg/mL for FDA999-1 and BR1005b) with detection by streptavidin-HRP (Biolegend) or anti-6xHis-HRP (Abcam). ..

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: Human colorectal carcinoma progression tissue microarray (CHTN-CRC2, Cooperative Human Tissue Network, University of Virginia) was stained with GlyTR1-FITC at 5 μg/mL before analysis by immunofluorescent microscopy (Aperio Versa 200, Model DM6 B, Leica). .. Human tissue microarrays from US Biomax (FDA999u, FDA999w and BR1005b), US Biolabs (FDA999-1), Novus Biologicals (NBP2-30169) and mouse (C57BL/6) tissue microarray from Pantomics (AMS545) were stained with L-PHA-biotin (0.25 μg/mL for FDA999u), GlyTR1 (0.5 μg/mL for FDA999w or 0.67 μg/mL for FDA999-1) or GlyTR2 (3 μg/mL for FDA999-1 and BR1005b) with detection by streptavidin-HRP (Biolegend) or anti-6xHis-HRP (Abcam). ..

    Positive Control:

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: .. Staining of metastatic colon cancer under the same conditions is shown as a positive control. (B–E) Normal human TMAs (FDA999w from BioMAx, B and C and FDA999-1 from US Biolabs, D and E), each containing 32 different tissues with replicates from 3 different individuals, along with a prostate cancer microarray (NBP2-30169 from Novus Biologicals) were stained with/without GlyTR1 with detection by anti6xHis-HRP antibody. ..

    Microarray:

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: .. Staining of metastatic colon cancer under the same conditions is shown as a positive control. (B–E) Normal human TMAs (FDA999w from BioMAx, B and C and FDA999-1 from US Biolabs, D and E), each containing 32 different tissues with replicates from 3 different individuals, along with a prostate cancer microarray (NBP2-30169 from Novus Biologicals) were stained with/without GlyTR1 with detection by anti6xHis-HRP antibody. ..

    Article Title: Fluid shear stress facilitates prostate cancer metastasis through Piezo1-Src-YAP axis.
    Article Snippet: .. Human prostate cancer tissue microarray (TMA) was purchased from Novus (NBP2-30169, Saint Charles, MO, USA). ..

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens
    Article Snippet: Human colorectal carcinoma progression tissue microarray (CHTN-CRC2, Cooperative Human Tissue Network, University of Virginia) was stained with GlyTR1-FITC at 5 μg/mL before analysis by immunofluorescent microscopy (Aperio Versa 200, Model DM6 B, Leica). .. Human tissue microarrays from US Biomax (FDA999u, FDA999w and BR1005b), US Biolabs (FDA999-1), Novus Biologicals (NBP2-30169) and mouse (C57BL/6) tissue microarray from Pantomics (AMS545) were stained with L-PHA-biotin (0.25 μg/mL for FDA999u), GlyTR1 (0.5 μg/mL for FDA999w or 0.67 μg/mL for FDA999-1) or GlyTR2 (3 μg/mL for FDA999-1 and BR1005b) with detection by streptavidin-HRP (Biolegend) or anti-6xHis-HRP (Abcam). ..

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens
    Article Snippet: Normal human tissue microarray , US Biolabs , FDA999-1. .. Prostate cancer microarray , Novus Biologicals , NBP2-30169. .. Breast cancer microarray , BioMAx , BR1005b.

    Article Title: The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with snRNP biogenesis machinery
    Article Snippet: The secondary antibody was biotinylated horse anti-rabbit IgG, R.T.U (#BP-1100-50) or horse anti-mouse IgG, R.T.U (#BP-2000-50) from Vector laboratories (Newark, CA, USA). .. Cytation 5 and Gen5 Image + software were used to quantify the IHC signal intensity on the prostate cancer tissue microarray, which was commercially available from Novus Biologicals (NBP2-30169) (Centennial, CO, USA). .. Statistics Page 7/26 Data in this study were analyzed using Prizm 8.0 (GraphPad, San Diego, CA, USA).

    Article Title: Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
    Article Snippet: Human colorectal carcinoma progression tissue microarray (CHTN-CRC2, Cooperative Human Tissue Network, University of Virginia) was stained with GlyTR1-FITC at 5 μg/mL before analysis by immunofluorescent microscopy (Aperio Versa 200, Model DM6 B, Leica). .. Human tissue microarrays from US Biomax (FDA999u, FDA999w and BR1005b), US Biolabs (FDA999-1), Novus Biologicals (NBP2-30169) and mouse (C57BL/6) tissue microarray from Pantomics (AMS545) were stained with L-PHA-biotin (0.25 μg/mL for FDA999u), GlyTR1 (0.5 μg/mL for FDA999w or 0.67 μg/mL for FDA999-1) or GlyTR2 (3 μg/mL for FDA999-1 and BR1005b) with detection by streptavidin-HRP (Biolegend) or anti-6xHis-HRP (Abcam). ..

    other:

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis
    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Software:

    Article Title: The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with snRNP biogenesis machinery
    Article Snippet: The secondary antibody was biotinylated horse anti-rabbit IgG, R.T.U (#BP-1100-50) or horse anti-mouse IgG, R.T.U (#BP-2000-50) from Vector laboratories (Newark, CA, USA). .. Cytation 5 and Gen5 Image + software were used to quantify the IHC signal intensity on the prostate cancer tissue microarray, which was commercially available from Novus Biologicals (NBP2-30169) (Centennial, CO, USA). .. Statistics Page 7/26 Data in this study were analyzed using Prizm 8.0 (GraphPad, San Diego, CA, USA).

    Immunohistochemistry:

    Article Title: The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with snRNP biogenesis machinery
    Article Snippet: The secondary antibody was biotinylated horse anti-rabbit IgG, R.T.U (#BP-1100-50) or horse anti-mouse IgG, R.T.U (#BP-2000-50) from Vector laboratories (Newark, CA, USA). .. Cytation 5 and Gen5 Image + software were used to quantify the IHC signal intensity on the prostate cancer tissue microarray, which was commercially available from Novus Biologicals (NBP2-30169) (Centennial, CO, USA). .. Statistics Page 7/26 Data in this study were analyzed using Prizm 8.0 (GraphPad, San Diego, CA, USA).



    Similar Products

    90
    Novus Biologicals case human prostate cancer tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Case Human Prostate Cancer Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/Human+Prostate+Tissue+MicroArray+(Cancer)/bio_rxiv__2025__11__12__687981-134-5-13
    Average 90 stars, based on 1 article reviews
    case human prostate cancer tma - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    US BIOLAB CORPORATION INC human prostate tissue microarrays (tmas) pr8011c
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Tissue Microarrays (Tmas) Pr8011c, supplied by US BIOLAB CORPORATION INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/human+prostate+tissue+microarrays++tmas++pr8011c/pmc11952371-48-0-8
    Average 90 stars, based on 1 article reviews
    human prostate tissue microarrays (tmas) pr8011c - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    92
    U.S Biomax Inc human multiple prostate cancer tissue microarrays tma pr483
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Multiple Prostate Cancer Tissue Microarrays Tma Pr483, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/pmc03027192-48-0-9
    Average 92 stars, based on 1 article reviews
    human multiple prostate cancer tissue microarrays tma pr483 - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    90
    Novus Biologicals human prostate cancer tissue microarray tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Cancer Tissue Microarray Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/Human+Prostate+Tissue+MicroArray+(Cancer)/pm36084759-113-0-9
    Average 90 stars, based on 1 article reviews
    human prostate cancer tissue microarray tma - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Novus Biologicals histopathology human prostate cancer tissue microarray tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Histopathology Human Prostate Cancer Tissue Microarray Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/Human+Prostate+Tissue+MicroArray+(Cancer)/10__21203_slash_rs__3__rs___1678497_slash_v1-177-0-10
    Average 90 stars, based on 1 article reviews
    histopathology human prostate cancer tissue microarray tma - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    U.S Biomax Inc the human prostate tissue microarray (tma) pr208a
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    The Human Prostate Tissue Microarray (Tma) Pr208a, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/Human+Prostate+Cancer/pmc08167398-42-1-10
    Average 90 stars, based on 1 article reviews
    the human prostate tissue microarray (tma) pr208a - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    U.S Biomax Inc human prostate tissue microarray (tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Tissue Microarray (Tma, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/prostate+cancer+tissue+arrays/pm31434609-48-6-12
    Average 90 stars, based on 1 article reviews
    human prostate tissue microarray (tma - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Johns Hopkins HealthCare human prostate tissue microarray (tma)
    AXL is not expressed in human prostate tumors. A, AXL expression prostate cancer patients who did and did not experience a biochemical recurrence (n = 1405 patients, GenomeDx GRID dataset). P value was calculated using the Wilcoxon rank test. B, Recurrence-free survival of patients with high (above the median) and low (below the median) AXL expression (n = 571 patients, Taylor et al, 2010 visualized and analyzed with Project Betastasis). C, Representative images of AXL IHC staining of a prostate tissue <t>microarray;</t> LN, lymph node. C42B cells served as a negative control, DU145 as a positive control. All images at original magnification x 200. D, AXL IHC staining in metastatic patient tissue; upper panel scale bar, 100 μm; lower panel scale bar, 50 μm.
    Human Prostate Tissue Microarray (Tma), supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/human+prostate+tissue+microarray++tma+/pmc06359976-167-0-12
    Average 90 stars, based on 1 article reviews
    human prostate tissue microarray (tma) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    92
    U.S Biomax Inc immunohistochemistry human prostate cancer tissue microarray tma
    AXL is not expressed in human prostate tumors. A, AXL expression prostate cancer patients who did and did not experience a biochemical recurrence (n = 1405 patients, GenomeDx GRID dataset). P value was calculated using the Wilcoxon rank test. B, Recurrence-free survival of patients with high (above the median) and low (below the median) AXL expression (n = 571 patients, Taylor et al, 2010 visualized and analyzed with Project Betastasis). C, Representative images of AXL IHC staining of a prostate tissue <t>microarray;</t> LN, lymph node. C42B cells served as a negative control, DU145 as a positive control. All images at original magnification x 200. D, AXL IHC staining in metastatic patient tissue; upper panel scale bar, 100 μm; lower panel scale bar, 50 μm.
    Immunohistochemistry Human Prostate Cancer Tissue Microarray Tma, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/pmc06125160-59-0-10
    Average 92 stars, based on 1 article reviews
    immunohistochemistry human prostate cancer tissue microarray tma - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    92
    U.S Biomax Inc human prostate cancer tissue microarray tma
    AXL is not expressed in human prostate tumors. A, AXL expression prostate cancer patients who did and did not experience a biochemical recurrence (n = 1405 patients, GenomeDx GRID dataset). P value was calculated using the Wilcoxon rank test. B, Recurrence-free survival of patients with high (above the median) and low (below the median) AXL expression (n = 571 patients, Taylor et al, 2010 visualized and analyzed with Project Betastasis). C, Representative images of AXL IHC staining of a prostate tissue <t>microarray;</t> LN, lymph node. C42B cells served as a negative control, DU145 as a positive control. All images at original magnification x 200. D, AXL IHC staining in metastatic patient tissue; upper panel scale bar, 100 μm; lower panel scale bar, 50 μm.
    Human Prostate Cancer Tissue Microarray Tma, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray+(tma)/pmc06125160-81-0-9
    Average 92 stars, based on 1 article reviews
    human prostate cancer tissue microarray tma - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

    Journal: bioRxiv

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

    doi: 10.1101/2025.11.12.687981

    Figure Lengend Snippet: ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Techniques: Immunohistochemistry, Staining

    ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

    Journal: bioRxiv

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

    doi: 10.1101/2025.11.12.687981

    Figure Lengend Snippet: ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Techniques: Immunohistochemistry, Generated, Microarray, Derivative Assay, Expressing

    AXL is not expressed in human prostate tumors. A, AXL expression prostate cancer patients who did and did not experience a biochemical recurrence (n = 1405 patients, GenomeDx GRID dataset). P value was calculated using the Wilcoxon rank test. B, Recurrence-free survival of patients with high (above the median) and low (below the median) AXL expression (n = 571 patients, Taylor et al, 2010 visualized and analyzed with Project Betastasis). C, Representative images of AXL IHC staining of a prostate tissue microarray; LN, lymph node. C42B cells served as a negative control, DU145 as a positive control. All images at original magnification x 200. D, AXL IHC staining in metastatic patient tissue; upper panel scale bar, 100 μm; lower panel scale bar, 50 μm.

    Journal: Molecular cancer research : MCR

    Article Title: AXL is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer

    doi: 10.1158/1541-7786.MCR-18-0718

    Figure Lengend Snippet: AXL is not expressed in human prostate tumors. A, AXL expression prostate cancer patients who did and did not experience a biochemical recurrence (n = 1405 patients, GenomeDx GRID dataset). P value was calculated using the Wilcoxon rank test. B, Recurrence-free survival of patients with high (above the median) and low (below the median) AXL expression (n = 571 patients, Taylor et al, 2010 visualized and analyzed with Project Betastasis). C, Representative images of AXL IHC staining of a prostate tissue microarray; LN, lymph node. C42B cells served as a negative control, DU145 as a positive control. All images at original magnification x 200. D, AXL IHC staining in metastatic patient tissue; upper panel scale bar, 100 μm; lower panel scale bar, 50 μm.

    Article Snippet: Human prostate tissue microarray (TMA) staining This study was approved by the Johns Hopkins institutional internal review board and followed the U.S. Common Rule.

    Techniques: Expressing, Immunohistochemistry, Microarray, Negative Control, Positive Control